Table 1. Sequences and MICs (μM) for the peptides and azithromycin used in this work.
| Peptides | MICa/MICac (μM) | MICb/MICbc (μM) | FICI | Sequence | Source |
|---|---|---|---|---|---|
| Api1b | 128/128 | >32/8 | 1.125 | GNNRPVYIPQPRPPHPRL | [18] |
| Oncocin | 128/128 | >32/8 | 1.125 | VDKPPYLPRPRPPRRIYNR | [25] |
| Pyrrhocoricin | 128/128 | >32/8 | 1.125 | VDKGSYLPRPTPPRPIYNRN-NH2 | [26] |
| EC5 | 128/8 | >32/8 | 0.188 | RLLFRKIRRLKR | [15] |
| D-EC5 | 128/128 | >32/8 | 1.125 | rllfrkirrlkr | This study |
| Bac8c | 128/128 | 4/1 | 1.250 | RIWVIWRR-NH2 | [16] |
| RW-BP100 | 128/128 | 8/2 | 1.250 | RRLFRRILRWL-NH2 | [17] |
| D-RW-BP100 | 128/128 | 8/2 | 1.250 | rrlfrrilrwl-NH2 | This study |
| D-RW-BP100R | 128/128 | 4/1 | 1.250 | lwrlirrflrr-NH2 | This study |
| LL-37 | 128/64 | 8/2 | 0.75 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | [27] |
| KR-12-a2 | 128/8 | 32/4 | 0.188 | KRIVQRIKKWLR-NH2 | [13] |
| L-11 | 128/4 | 32/4 | 0.156 | RIVQRIKKWLR-NH2 | [14] |
| D-11 | 128/4 | 32/4 | 0.156 | rivqrikkwlr-NH2 | [14] |
| D-11R | 128/4 | 32/4 | 0.156 | rlwkkirqvirk-NH2 | [14] |
| L-11-R5W | 128/128 | 4/1 | 1.250 | RIVQWIKKWLR-NH2 | This study |
| D-11-k(r) | 128/4 | 32/4 | 0.156 | rivqrirrwlr-NH2 | This study |
| PEP9 | 128/128 | >32/8 | 1.125 | NGVQPKYK | [28] |
| PEP10 | 128/128 | >32/8 | 1.125 | KIAKVALKALK | [29] |
| ADP-1 | 128/128 | 16/4 | 1.125 | GIGKHVGKALKGLKGLLKGLGEC | [30] |
| ADP-1a | 128/128 | >32/8 | 1.125 | LKGLKGLLKGLGEC | This study |
| ADP-1b | 128/128 | >32/8 | 1.125 | KHVGKALKGLK | This study |
| ADP-1c | 128/128 | >32/8 | 1.125 | LKGLKGLLKGL | This study |
MICa: the MIC of azithromycin, MICb: the MIC of the peptide, MICac: the MIC of azithromycin in the combination, MICbc: the MIC of the peptide in the combination, the synergy effects were bolded in FICI. Peptides with capital letters mean they are synthesized with L-type amino acids, peptides with lowercase letters mean they are synthesized with D-type amino acids, red marks mean amino acid changes. D-11 and its variants were derived from the sequence that was bolded in LL-37 peptide.